1Galie N, Manes A, Negro L, et al. A recta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J, 2009, 30: 394-403. 被引量：1
2McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation, 2002, 106 : 1477-1482. 被引量：1
3Barst RJ. Recent advances in the treatment of pediatric pulmonary artery hypertension. Pedlatr Clin North Am, 1999, 46: 331-345. 被引量：1
4McLaughlin VV, Sithon O, Badesch DB, et al. Survival with first- line bosentan in patients with primary pulmonary hypertension. Eur Respir J, 2005, 25 : 244-249. 被引量：1
5Galie N, Ghofrani HA, Torbicki A, et al. Sildenalil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 2005, 353 : 2148-2157. 被引量：1
6Gomberg-Maifland M, Dufton C, Oudiz RJ. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol, 2011,57: 1053-1061. 被引量：1
7Macehia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J, 2007, 153 : 1037- 1047. 被引量：1
8D'Alonzo GE,Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry [ J]. Ann Intern Med, 1991,115 : 343-349. 被引量：1
9McLaughlin VV, Suissa S. Prognosis of pulmonary arterial hypertension: the power of clinical registries of rare diseases [ J]. Circulation ,2010,122 : 106-108. 被引量：1
10Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension [ J ]. J Am Coil Cardiol, 2013,62: D34-D41. 被引量：1
